title: Coronary bifurcation stenting. Current techniques, outcome and possible future developments.
abstract: Percutaneous treatment of coronary bifurcation lesions remained challenging in the stent era, with restenosis rates greater than 30% and no advantage from the routine use of kissing stents. Drug eluting stents (DES) have dramatically reduced the restenosis rates (RR) in the main vessel, but with conventional T-stenting double digits figures are still reported for the side-branch because of poor ostial coverage. The techniques of kissing stenting able to provide full lesion coverage (Culotte, V-stenting, Crush) have the potential to improve these results but the development of dedicated DES is probably needed to obtain consistently high procedural and long-term success.
authors.affiliation: Department of Cardiology, Guy's King's and St Thomas' School of Medicine King's College Hospital, Denmark Hill, London, UK.
authors.forename: N
authors.initials: N
authors.lastname: Melikian
authors.forename: F
authors.initials: F
authors.lastname: Airoldi
authors.forename: C
authors.initials: C
authors.lastname: Di Mario
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D023903:Coronary Restenosis / Q000517:prevention & control; D023921:Coronary Stenosis / Q000145:classification / Q000628:therapy*; D004359:Drug Therapy, Combination; D004867:Equipment Design; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus